(2R)-2,4-Dimethylpiperazine-1-carboxylic acid 4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl ester is a complex, chirally pure organic compound featuring a quinazoline core linked to a substituted piperazine via a carbamate ester. Its structure is characteristic of a key synthetic intermediate in pharmaceutical development. This compound is a crucial intermediate in the synthesis of Lazertinib (YH25448, GNS-1480), a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Lazertinib is specifically designed to target EGFR mutations, including T790M, which are associated with resistance to earlier-generation EGFR inhibitors in non-small cell lung cancer (NSCLC) treatment. The (2R)-2,4-dimethylpiperazine moiety is a critical structural component contributing to the drug's potency and selectivity. As a high-value pharmaceutical intermediate, its synthesis and supply are essential for the production of the active pharmaceutical ingredient (API) Lazertinib. Handling requires standard precautions for fine chemicals in a controlled laboratory or manufacturing environment.